<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100888</url>
  </required_header>
  <id_info>
    <org_study_id>TB-rTMS_SCH2021</org_study_id>
    <nct_id>NCT05100888</nct_id>
  </id_info>
  <brief_title>Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms</brief_title>
  <acronym>tbTMS_SCH21</acronym>
  <official_title>Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms: a Double-blind, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Semmelweis University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major target of the study is to confirm the safety and efficacy of our augmented protocol&#xD;
      of theta-burst TMS in schizophrenia. Our aim is to confirm the beneficial effects of rTMS&#xD;
      treatment on multiple aspects of the disorder such as (1) clinical aspect in terms of PANSS,&#xD;
      (2) cognitive aspect such as emotion recognition (ER) and working memory (WM) / distractor&#xD;
      filtering (DF) performance, and (3) neurobiology in terms of electrophysiology correlates of&#xD;
      ER, WM and DF such as event related theta synchronization, resting state theta power, and&#xD;
      network connectivity. Response prediction to (theta-burst) TB-rTMS will be the exploratory&#xD;
      part of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale, Negative subscore</measure>
    <time_frame>4 weeks</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of patients with schizophrenia. It is the gold standard in the treatment monitoring of schizophrenia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive functioning</measure>
    <time_frame>4 weeks</time_frame>
    <description>The Digit Span Forward and Backward tests will be used to assess working memory, while the Wisconsin Card Sorting test will be used to measure cognitive flexibility. Attention will be assessed by the Stroop task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social cognition</measure>
    <time_frame>4 weeks</time_frame>
    <description>The Baron-Cohen 'Reading the Mind in the Eyes Test ' and the 'Faux Pas' test will be used to assess social cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety in terms of adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Safety in terms of the number of serious adverse events (SAE).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Transcranial Magnetic Stimulation Repetitive</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Theta-burst rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Theta-burst repetitive transcranial magnetic stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham stimulation of the same location</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive Transcranial Magnetic Stimulation (rTMS)</intervention_name>
    <description>Theta-burst stimulation</description>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_label>Theta-burst rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. diagnosis of schizophrenia or schizoaffective disorder;&#xD;
&#xD;
          2. clinically stabilized on antipsychotic: a stable dose of antipsychotic medication for&#xD;
             &gt;4 weeks;&#xD;
&#xD;
          3. age 18-50 years, and&#xD;
&#xD;
          4. presence of negative symptoms (based on PANSS): a negative subscore ≥16 points and&#xD;
             [one of items N1-N7 scoring ≥4 or two items N1-N7 scoring ≥3]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. any significant neurological illness;&#xD;
&#xD;
          2. mental retardation&#xD;
&#xD;
          3. history of head injury with loss of consciousness for more than 1 hour&#xD;
&#xD;
          4. history of epileptic seizures or epileptic activity on the baseline EEG (evaluated by&#xD;
             an expert in clinical EEG and epilepsy),&#xD;
&#xD;
          5. alcohol or drug abuse within the past 3 months, and&#xD;
&#xD;
          6. depressive episode or antidepressant treatment in the past 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gábor Csukly, MDd, PhD</last_name>
    <phone>+36208250174</phone>
    <email>csukly.gabor@med.semmelweis-univ.hu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Boglárka Orbán-Szigeti, MD</last_name>
    <email>orban-szigeti.boglarka@med.semmelweis-univ.hu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Semmelweis University</investigator_affiliation>
    <investigator_full_name>Gábor Csukly</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurobehavioral Manifestations</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

